Antihistamine and aspirin with immunotherapy for solid tumors
Treatments studied
Part of Cancer, Immune system & allergy clinical trials.
This trial tests whether taking a daily antihistamine (like Claritin) and a daily aspirin alongside your immunotherapy can make the treatment work better. It's for people with solid tumors who are about to start a PD-1 or PD-L1 blocker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that can be measured on scans (early or advanced stage).
- Your treatment plan includes an immunotherapy drug (PD-1 or PD-L1 inhibitor) as standard care.
- You are willing to stop using THC products (including marijuana, CBD) for the study.
- You are willing to take a daily antihistamine (loratadine) and a daily aspirin (or similar NSAID).
- You are not on blood thinners or antiplatelet drugs that raise bleeding risk, and you have no allergy to aspirin or loratadine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests a new cancer drug (S-531011) in people with advanced or metastatic solid tumors, either by itself or combined with an immunotherapy drug. It may help shrink tumors and learn how the treatment works, but it also requires extra procedures like repeat tumor biopsies and frequent monitoring.
This study watches people with solid tumors who are starting immunotherapy for the first time. It aims to predict and better understand side effects and how well the treatment works, to help doctors manage care more effectively.
This study tests whether adding an antihistamine (a common allergy medicine) to the usual combination of an immunotherapy drug (toripalimab) and chemotherapy, given before and after surgery, helps treat stage II or III non-small cell lung cancer better than without it.
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
This study looks at how common medicines might interact with immunotherapy (a treatment that helps your immune system fight cancer). Participation could help doctors learn how to better manage side effects and dosing for patients on these treatments.
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Hear when a new Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.